Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2008
|
| gptkbp:focus |
cardiovascular diseases
pulmonary arterial hypertension |
| gptkbp:founded |
1988
|
| gptkbp:headquartersLocation |
gptkb:Houston,_Texas,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Encysive Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
Thelin (sitaxentan sodium)
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
ENCY
|
| gptkbp:bfsParent |
gptkb:Texas_Biotechnology
|
| gptkbp:bfsLayer |
8
|